Profile
Sector:
HealthcareCountry:
United StatesIPO:
01 February 2013Website:
http://www.zoetis.comNext earnings report:
08 August 2024Last dividends:
18 April 2024Next dividends:
18 July 2024Price
after hours | Wed, 03 Jul 2024 20:00:00 GMTAnalysts recommendations
Institutional Ownership
Included in screeners
ZTS Latest News
Zoetis's stock has slumped in 2024, partly due to recent safety concerns regarding the company's arthritis drugs. Despite these safety concerns, Zoetis grew total revenue by 10% compared to Q1 2023 and raised their full-year 2024 revenue guidance. The company's companion animal products are supporting Zoetis's growth as the company sees a large opportunity with their osteoarthritis pain drugs.
Zoetis is a resilient company that shows strong growth even in times of economic challenges. The company is well-positioned in a growing market and has a strong product portfolio, including a new potential billion-franchise in osteoarthritis pain. ZTS has shown impressive dividend growth in recent years, and it is likely this will continue in the future, making it attractive for dividend investors with a long time horizon.
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Zoetis CEO Kristin Peck joins 'Mad Money' host Jim Cramer to talk the state of pet health care, research and development investments, Avian Flu treatments and more.
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DriventoCare--As animals and communities continue to face mounting challenges from natural disasters, Zoetis Inc. and the Zoetis Foundation are committed to supporting animal health and community resilience. The Zoetis Foundation brings this commitment to life through grant support to the American Red Cross, which will help provide necessary emergency preparedness and relief to families and communities impacted by disasters. Zoetis Inc. partners with American Humane to incr.
What type of business is Zoetis?
Zoetis Inc. is an American pharmaceutical company headquartered in Parsippany, New Jersey, specializing in the development, production, and sale of veterinary medicines, vaccines, and diagnostic products for the livestock and pets industry. It was founded in 2012 as a spin-off from the largest drug manufacturer, Pfizer Inc. The company is one of the largest in its industry. Its main competitive advantages include: an extensive network of technical and veterinary operations specialists, high-quality production and reliable supply, years of experience, strong customer relationships, ongoing research and development (R&D), and more.
What sector is Zoetis in?
Zoetis is in the Healthcare sector
What industry is Zoetis in?
Zoetis is in the Drug Manufacturers - Specialty & Generic industry
What country is Zoetis from?
Zoetis is headquartered in United States
When did Zoetis go public?
Zoetis initial public offering (IPO) was on 01 February 2013
What is Zoetis website?
https://www.zoetis.com
Is Zoetis in the S&P 500?
Yes, Zoetis is included in the S&P 500 index
Is Zoetis in the NASDAQ 100?
No, Zoetis is not included in the NASDAQ 100 index
Is Zoetis in the Dow Jones?
No, Zoetis is not included in the Dow Jones index
When does Zoetis report earnings?
The next expected earnings date for Zoetis is 08 August 2024